Financial Performance - The company's revenue for Q1 2025 was ¥99,852,532.57, representing a 1.99% increase compared to ¥97,906,175.23 in the same period last year[5] - Net profit attributable to shareholders decreased by 7.31% to ¥8,883,353.43 from ¥9,583,923.21 year-on-year[5] - Total operating revenue for the current period reached ¥99,852,532.57, an increase of 1.0% compared to ¥97,906,175.23 in the previous period[26] - Net profit for the current period was ¥8,883,353.43, a decrease of 7.3% from ¥9,583,923.21 in the previous period[27] - Total comprehensive income attributable to the parent company was CNY 8,883,353.43, down from CNY 9,583,923.21 in the previous period, representing a decrease of approximately 7.3%[28] - Basic and diluted earnings per share decreased to CNY 0.0628 from CNY 0.0660, reflecting a decline of about 4.8%[28] Cash Flow - The net cash flow from operating activities increased significantly by 46.88% to ¥30,632,040.30, up from ¥20,854,970.76 in the previous year[5] - Cash inflow from operating activities totaled CNY 144,506,085.85, compared to CNY 114,185,746.23 in the previous period, an increase of approximately 26.5%[31] - The company's cash flow from operating activities was positively impacted by a tax refund of CNY 1,525,794.35, compared to CNY 294,294.67 in the previous period[30] - The net cash flow from financing activities was negative at -¥18,011,119.25, a 359.87% increase in outflow compared to -¥3,916,568.29 in the previous year, primarily due to stock buybacks[14] - Cash outflow from investing activities was CNY 20,558,202.98, compared to CNY 29,626,258.50 in the previous period, a decrease of about 30.5%[31] Assets and Liabilities - The total assets at the end of the reporting period were ¥768,673,593.86, a decrease of 2.73% from ¥790,269,703.56 at the end of the previous year[5] - Total liabilities decreased to ¥32,952,719.74 from ¥45,421,063.62, a reduction of 27.5%[25] - Cash and cash equivalents at the end of the period were ¥276,879,255.87, an increase of 6.1% from ¥260,247,859.66 at the beginning of the period[23] - Accounts receivable decreased to ¥72,109,685.30 from ¥104,448,085.77, a reduction of 30.9%[23] - Inventory slightly decreased to ¥66,843,604.90 from ¥67,480,355.15, a decline of 0.9%[24] Investments and Projects - The company reported a 319.10% increase in construction in progress, amounting to ¥18,659,629.01, primarily due to the commencement of the corn protein deep processing project[9] - The company received a construction permit for its 100,000-ton corn protein processing project, which is crucial for project advancement[21] - A new utility model patent was granted for a wastewater recovery and treatment system in March 2025[21] - The company reported a significant increase in research and development expenses, which rose to ¥4,546,502.11 from ¥4,123,227.36, an increase of 10.3%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,290[16] - The largest shareholder, Hong Wei, holds 39.44% of the shares, totaling 55,527,272 shares[16] - The company has a total of 76,409,406 restricted shares at the end of the reporting period[20] - The company completed the cancellation of 4,406,765 repurchased shares, reducing the total share capital from 145,191,440 to 140,784,675 shares[21] - The company has no changes in the shareholding structure of the top 10 shareholders due to securities lending[17] Income and Expenses - Total operating costs amounted to ¥91,829,115.62, up from ¥88,010,714.31, reflecting a rise of 4.1%[26] - The company reported a 46.94% decrease in other income, totaling ¥340,645.75, mainly due to changes in government subsidies received[13] - Investment income for the period was ¥289,668.72, a significant improvement of 179.43% compared to a loss of ¥364,692.95 in the previous year[13]
美农生物(301156) - 2025 Q1 - 季度财报